keyword
https://read.qxmd.com/read/36941274/clonal-dynamics-of-alloreactive-t-cells-in-kidney-allograft-rejection-after-anti-pd-1-therapy
#21
JOURNAL ARTICLE
Garrett S Dunlap, Daniel DiToro, Joel Henderson, Sujal I Shah, Mike Manos, Mariano Severgnini, Astrid Weins, Indira Guleria, Patrick A Ott, Naoka Murakami, Deepak A Rao
Kidney transplant recipients are at particular risk for developing tumors, many of which are now routinely treated with immune checkpoint inhibitors (ICIs); however, ICI therapy can precipitate transplant rejection. Here, we use TCR sequencing to identify and track alloreactive T cells in a patient with melanoma who experienced kidney transplant rejection following PD-1 inhibition. The treatment was associated with a sharp increase in circulating alloreactive CD8+ T cell clones, which display a unique transcriptomic signature and were also detected in the rejected kidney but not at tumor sites...
March 21, 2023: Nature Communications
https://read.qxmd.com/read/36906296/a-rare-skin-lesion-in-a-kidney-transplant-recipient
#22
JOURNAL ARTICLE
Fernando Caravaca-Fontán, Laura Ibarra, José Luis Rodríguez-Peralto, Eduardo Gutiérrez
No abstract text is available yet for this article.
March 2023: American Journal of Transplantation
https://read.qxmd.com/read/36808609/propensity-score-matched-analysis-of-long-term-outcomes-for-living-kidney-donation-in-alternative-complement-pathway-diseases-a-pilot-study
#23
JOURNAL ARTICLE
Yasar Caliskan, Seda Safak, Ozgur Akin Oto, Arzu Velioglu, Berna Yelken, Safak Mirioglu, Ahmet Burak Dirim, Abdulmecit Yildiz, Nurana Guller, Halil Yazici, Alparslan Ersoy, Aydin Turkmen, Krista L Lentine
BACKGROUND: Atypical hemolytic syndrome (aHUS) and C3 glomerulopathy (C3G) are complement-mediated rare diseases with excessive activation of the alternative pathway. Data to guide the evaluation of living-donor candidates for aHUS and C3G are very limited. The outcomes of living donors to recipients with aHUS and C3G (Complement disease-living donor group) were compared with a control group to improve our understanding of the clinical course and outcomes of living donation in this context...
February 20, 2023: Journal of Nephrology
https://read.qxmd.com/read/36706163/immune-checkpoint-inhibitors-in-solid-organ-transplant-recipients-with-advanced-skin-cancers-emerging-strategies-for-clinical-management
#24
JOURNAL ARTICLE
Carla Ferrándiz-Pulido, Ulrike Leiter, Catherine Harwood, Charlotte M Proby, Martina Guthoff, Christina H Scheel, Timm H Westhoff, Jan Nico Bouwes Bavinck, Thomas Meyer, Mirjam C Nägeli, Veronique Del Marmol, Celeste Lebbé, Alexandra Geusau
Use of immune checkpoint inhibitors (ICIs) in solid organ transplant recipients (SOTRs) with advanced skin cancers presents a significant clinical management dilemma. SOTRs and other immunosuppressed patients have been routinely excluded from ICI clinical trials with good reason: immune checkpoints play an important role in self- and allograft-tolerance and risk of acute allograft rejection reported in retrospective studies affects 10% to 65% of cases. These reports also confirm that cutaneous squamous cell carcinoma and melanoma respond to ICI therapy, although response rates are generally lower than those observed in immunocompetent populations...
July 1, 2023: Transplantation
https://read.qxmd.com/read/36683232/variations-in-risk-of-cancer-and-death-from-cancer-according-to-kidney-allograft-function-graft-loss-and-return-to-dialysis
#25
JOURNAL ARTICLE
Eric H K Au, Jeremy R Chapman, Armando Teixeira-Pinto, Jonathan C Craig, Germaine Wong
BACKGROUND: Cancer incidence and mortality may change with varying kidney allograft function and after graft loss. We aimed to quantify cancer incidence and mortality during periods with a functioning graft and after graft loss. METHODS: We included all adult Australians aged 20 and above who commenced kidney replacement therapy between 1982 and 2014 using data from Australia and New Zealand Dialysis and Transplant Registry. We calculated the standardized incidence ratios and standardized mortality ratios (standardized against the Australian general population) for dialysis patients and transplant recipients during periods with a functioning graft and after graft loss...
January 23, 2023: Transplantation
https://read.qxmd.com/read/36579684/immune-checkpoint-inhibitors-in-kidney-transplantation
#26
REVIEW
Nora Alzahrani, Ayman Al Jurdi, Leonardo V Riella
PURPOSE OF REVIEW: The development of immune checkpoint inhibitor (ICI) immunotherapy has revolutionized the treatment of several cancers. Malignancies are one of the leading causes of death in solid organ transplant recipients (SOTRs). Although ICI treatment may be an effective option in treating malignancies in SOTRs, concerns about triggering allograft rejection have been raised in this population. Herein, we will review currently available data regarding patients, allograft and malignancy outcomes in SOTRs who received ICI therapy...
February 1, 2023: Current Opinion in Organ Transplantation
https://read.qxmd.com/read/36575360/cd19-car-t-therapy-in-solid-organ-transplant-recipients-case-report-and-systematic-review
#27
REVIEW
Andrew J Portuguese, Jordan Gauthier, Scott S Tykodi, Evan T Hall, Alexandre V Hirayama, Cecilia C S Yeung, Christopher D Blosser
Post-transplant lymphoproliferative disorder (PTLD) is a leading cause of cancer death in solid organ transplant recipients (SOTRs). Relapsed or refractory (R/R) PTLD portends a high risk of death and effective management is not well established. CD19-targeted CAR-T cell therapy has been utilized, but the risks and benefits are unknown. We report the first case of diffuse large B-cell lymphoma (DLBCL) PTLD treated with lisocabtagene maraleucel and present a systematic literature review of SOTRs with PTLD treated with CD19 CAR-T therapy...
April 2023: Bone Marrow Transplantation
https://read.qxmd.com/read/36572322/reconstruction-of-primary-and-secondary-aortic-infections-with-an-antimicrobial-graft
#28
JOURNAL ARTICLE
Caroline Caradu, Benjamin Jolivet, Mathilde Puges, Charles Cazanave, Eric Ducasse, Xavier Berard
INTRODUCTION: In situ reconstruction (ISR) with autologous veins is the preferred method in infectious native aortic aneurysms (INAAs) or vascular (endo)graft infection (VGEI). However, access to biological substitutes can prove difficult and lacks versatility. This study evaluates survival and freedom from reinfection after ISR of INAA/VGEI using the antimicrobial Intergard Synergy graft combining silver and triclosan. METHODS: From February 2014 to April 2020, 86 antimicrobial grafts were implanted for aortic infection...
April 2023: Journal of Vascular Surgery
https://read.qxmd.com/read/36564224/standardizing-health-outcomes-for-chronic-kidney-disease-adaptation-of-the-international-consortium-for-health-outcomes-measurement-standard-set-to-the-spanish-setting
#29
JOURNAL ARTICLE
Eduardo Parra, Mercedes Salgueira, Jose Portolés, Pablo Serrano, Beatriz Bayés, Joaquín Estévez, María Dolores Del Pino
BACKGROUND AND OBJECTIVES: We aim to adapt the International Consortium for Health Outcomes Measurements standard set for chronic kidney disease (CKD) patients to the Spanish setting and supplement it with those variables agreed upon through initiatives proposed by the Spanish Society of Nephrologists (S.E.N.). MATERIAL AND METHODS: The working group defined a first standard set of variables based on a literature review. The S.E.N. members then assessed the suitability of each variable for inclusion (Consensus≥75%)...
December 21, 2022: Nefrología
https://read.qxmd.com/read/36252821/new-immunosuppressive-agents-in-transplantation
#30
JOURNAL ARTICLE
Delphine Kervella, Gilles Blancho
Immunosuppressive agents have enabled the development of allogenic transplantation during the last 40 years, allowing considerable improvement in graft survival. However, several issues remain such as the nephrotoxicity of calcineurin inhibitors, the cornerstone of immunosuppressive regimens and/or the higher risk of opportunistic infections and cancers. Most immunosuppressive agents target T cell activation and may not be efficient enough to prevent allo-immunization in the long term. Finally, antibody mediated rejection due to donor specific antibodies strongly affects allograft survival...
December 2022: La Presse Médicale
https://read.qxmd.com/read/36251070/tertiary-lymphoid-tissues-in-kidney-diseases-a-perspective-for-the-pediatric-nephrologist
#31
JOURNAL ARTICLE
Takahisa Yoshikawa, Yu Ho Lee, Yuki Sato, Motoko Yanagita
Chronic kidney disease (CKD) is a major public health problem worldwide. In the pediatric population, CKD is also an important health issue because it causes several comorbid conditions that can have long-term consequences beyond the pediatric age. Chronic inflammation is a common pathological feature of CKD, irrespective of etiology, and leads to maladaptive repair and kidney dysfunction. Tertiary lymphoid tissues (TLTs) are ectopic lymphoid structures that develop in non-lymphoid organs under chronic inflammation caused by pathological conditions, including infections, autoimmune diseases, and cancers...
October 17, 2022: Pediatric Nephrology
https://read.qxmd.com/read/36210692/solid-renal-mass-in-a-transplanted-allograft-kidney-mucinous-tubular-and-spindle-cell-renal-cell-carcinoma
#32
Erdinc Dincer, Osman Murat Ipek, Sukran Sarikaya Kayipmaz, Oktay Akca
Renal transplantation is the main treatment for end-stage kidney disease. Transplantation reduces the mortality rate and increases life quality in this population but cancer in allograft kidney is a major problem. Here, we report a 39-year male who had renal transplantation 10 years ago. On routine follow-up, radiologic imaging revealed a 32 mm mass in the allograft kidney. After partial nephrectomy, histopathologic examination revealed mucinous tubular and spindle cell variant of renal cell carcinoma(MTSCC)...
August 2022: Journal of the College of Physicians and Surgeons—Pakistan: JCPSP
https://read.qxmd.com/read/36186846/carbon-dots-conjugated-to-sn38-for-improved-colorectal-anticancer-therapy
#33
JOURNAL ARTICLE
Deborah Mattinzoli, Michele Cacioppo, Masami Ikehata, Silvia Armelloni, Carlo Maria Alfieri, Giuseppe Castellano, Mario Barilani, Francesca Arcudi, Piergiorgio Messa, Maurizio Prato
Irinotecan (CTP-11) is one of the standard therapies for colorectal cancer (CRC). CTP-11 is enzymatically converted to the hydrophobic 7-ethyl-10-hydroxycamptothecin (SN38), a one hundred-fold more active metabolite. Conjugation of hydrophobic anticancer drugs to nanomaterials is a strategy to improve their solubility, efficacy, and selectivity. Carbon dots (CDs) have garnered interest for their small sizes (<10 ​nm), low toxicity, high water solubility, and bright fluorescence. This paper describes the use of CDs to improve drug vehiculation, stability, and chemotherapeutic efficiency of SN38 through a direct intracellular uptake in CRC...
December 2022: Materials today. Bio
https://read.qxmd.com/read/36159360/current-status-of-adverse-event-profile-of-cyclosporine-in-kidney-stem-cell-and-heart-transplantations-using-the-japanese-pharmacovigilance-database
#34
JOURNAL ARTICLE
Iku Niinomi, Saki Oyama, Ayaka Inada, Tomohito Wakabayashi, Tatsuya Iida, Hiroko Kambara, Mayako Uchida, Yukako Sano, Keiko Hosohata
BACKGROUND: Cyclosporine is widely used to prevent allograft rejection after transplantation. The purpose of this study was to clarify the adverse events profiles associated with cyclosporine in transplant patients using a spontaneous reporting system database. METHODS: Retrospective pharmacovigilance disproportionality analysis was conducted using the Japanese Adverse Drug Event Report (JADER) database, with the reporting odds ratio (ROR) and 95% confidence interval (CI) for each adverse event...
September 2022: Curēus
https://read.qxmd.com/read/36149031/extracellular-vesicle-bound-dna-in-urine-is-indicative-of-kidney-allograft-injury
#35
JOURNAL ARTICLE
Ivana Sedej, Maja Štalekar, Magda Tušek Žnidarič, Katja Goričar, Nika Kojc, Polona Kogovšek, Vita Dolžan, Miha Arnol, Metka Lenassi
Extracellular vesicle-bound DNA (evDNA) is an understudied extracellular vesicle (EV) cargo, particularly in cancer-unrelated research. Although evDNA has been detected in urine, little is known about its characteristics, localization, and biomarker potential for kidney pathologies. To address this, we enriched EVs from urine of well-characterized kidney transplant recipients undergoing allograft biopsy, characterized their evDNA and its association to allograft injury. The SEC-based method enriched pure EVs from urine of kidney transplant recipients, regardless of the allograft injury...
September 2022: Journal of Extracellular Vesicles
https://read.qxmd.com/read/36129920/donor-derived-urologic-cancers-after-renal-transplantation-a-retrospective-non-randomized-scientific-analysis
#36
JOURNAL ARTICLE
Vivan Hellström, Gunnar Tufveson, Angelica Loskog, Mats Bengtsson, Gunilla Enblad, Tomas Lorant
BACKGROUND: Malignancies in the urinary tract and the kidney graft are quite common after kidney transplantation. In some selected cases tumours develop from donor-derived tissue. OBJECTIVES: We hypothesised that there is a clinical value to investigate donor/recipient origin in urologic malignancies in renal transplant recipients. METHODS: In this retrospective study, including patients transplanted between the years 1969 and 2014 at Uppsala University Hospital, Sweden, 11 patients with malignancies in urinary tract and 4 patients with malignancies in kidney transplants were investigated...
2022: PloS One
https://read.qxmd.com/read/36109426/revisiting-maintenance-immunosuppression-in-patients-with-renal-transplant-failure-early-weaning-of-immunosuppression-versus-prolonged-maintenance-systematic-review-and-meta-analysis
#37
REVIEW
Anas Elgenidy, Rasha Samir Shemies, Mostafa Atef, Ahmed K Awad, Hatem H El-Leithy, Mohamed Helmy, Mostafa G Aly
INTRODUCTION: Prolonged immunosuppression after dialysis start has been assumed to reduce sensitization, need for graft nephrectomy, and to favor re-transplantation. In contrast, immunosuppression is considered to increase the risk of mortality, infection, and malignancy. We aimed to assess the evidence regarding superiority of early or late withdrawal of maintenance immunosuppression post renal transplant failure. METHODS: A literature search of the PubMed, WOS, Ovid, and Scopus databases was conducted...
September 15, 2022: Journal of Nephrology
https://read.qxmd.com/read/35998321/malignancies-in-adult-kidney-transplant-candidates-and-recipients-current-status
#38
JOURNAL ARTICLE
Krystyna Serkies, Alicja Dębska-Ślizień, Anna Kowalczyk, Sławomir Lizakowski, Jolanta Małyszko
Posttransplant malignancies, particularly recurrent and de novo, in solid organs including kidney transplant recipients (KTRs) are a significant complication associated with substantial mortality, largely attributed to the long-term immunosuppression necessary to maintain allograft tolerance. Older age at transplantation and oncogenic virus infection along with pretransplant malignancies are among the main factors contributing to the risk of cancer in this population. As the mean age of transplant candidates rises, the rate of transplant recipients with pretransplant malignancies also increases...
June 30, 2023: Nephrology, Dialysis, Transplantation
https://read.qxmd.com/read/35988897/higher-mycophenolate-dosage-is-associated-with-an-increased-risk-of-squamous-cell-carcinoma-in-kidney-transplant-recipients
#39
JOURNAL ARTICLE
E X Shao, B Betz-Stablein, L Marquat, S Campbell, N Isbel, A C Green, E I Plasmeijer
BACKGROUND: Kidney transplant recipients are at increased risk of keratinocyte cancers, namely squamous cell and basal cell carcinomas (SCCs and BCCs). This is primarily due to the high levels of immunosuppression that are required to prevent allograft rejection. Different immunosuppressive medications confer different risks, and the effect of mycophenolate mofetil on SCC and BCC risk is unclear. We explored the relationship between mycophenolate dose prescribed over the entire transplant period and the risk of SCC and BCC...
August 18, 2022: Transplant Immunology
https://read.qxmd.com/read/35988467/antibody-mediated-allograft-rejection-is-associated-with-an-increase-in-peripheral-differentiated-cd28-cd8-t-cells-analyses-of-a-cohort-of-1032-kidney-transplant-recipients
#40
JOURNAL ARTICLE
Hoa Le Mai, Nicolas Degauque, Sabine Le Bot, Marie Rimbert, Karine Renaudin, Richard Danger, Florent Le Borgne, Clarisse Kerleau, Gaelle Tilly, Anaïs Vivet, Florent Delbos, Alexandre Walencik, Magali Giral, Sophie Brouard
BACKGROUND: CD28-CD8+ T cells represent a differentiated CD8+ T cell subset that is found to be increased in various conditions associated with chronic antigenic stimulation such as aging, chronic viral infections, autoimmune diseases, cancers, and allotransplantation. METHODS: Using multivariate models, we analyzed a large cohort of 1032 kidney transplant patients in whom 1495 kidney graft biopsies were performed concomitant with a peripheral blood leukocyte phenotyping by flow cytometry...
August 18, 2022: EBioMedicine
keyword
keyword
117730
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.